First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.

Sunvozertinib significantly improves progression-free survival compared to chemotherapy as a first-line treatment for NSCLC with EGFR exon 20 insertions, with a median of 10.3 versus 7.5 months.

• Why it matters: Effective first-line options for NSCLC with EGFR exon 20 insertions are limited, and current therapies often have suboptimal outcomes, highlighting the need for targeted treatments with better efficacy and safety profiles.
• What they did: A phase 3 trial randomly assigned 324 patients to receive sunvozertinib or chemotherapy, measuring progression-free survival, objective response, tumor size change, and safety outcomes.
• The result: Sunvozertinib demonstrated superior efficacy, with higher objective response rates and longer response durations, though it was associated with more grade 3 or higher adverse events, supporting its potential as a first-line therapy.